L'efficience de ce dernier pour la société sera mesurée grâce à la comparaison des moyens employés (coûts) avec les résultats obtenus ,
arrêté d'inscription de l'anticorps anti-intégrine ?4ß7 sur la liste des médicaments remboursables ainsi que les avis de fixation du taux de remboursement et du prix seront publiés de façon ,
Etiology of Crohn???s disease: many roads lead to autophagy, Journal of Molecular Medicine, vol.3, issue.9, pp.987-96, 2012. ,
DOI : 10.1007/s00109-012-0934-8
Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis, Nature Clinical Practice Gastroenterology & Hepatology, vol.124, issue.7 ,
DOI : 10.1038/ncpgasthep0528
Inflammatory bowel disease: Pathogenesis, World Journal of Gastroenterology, vol.20, issue.1, pp.91-100, 2014. ,
DOI : 10.3748/wjg.v20.i1.91
Burden of Crohn's disease : economics and quality of life aspects in Italy, ClinicoEcon Outcomes Res, vol.4, pp.209-227, 2012. ,
Immunopathology of inflammatory bowel disease, World Journal of Gastroenterology, vol.20, issue.1, pp.6-21, 2014. ,
DOI : 10.3748/wjg.v20.i1.6
Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review, Gastroenterology, vol.142, issue.1, pp.46-54, 2012. ,
DOI : 10.1053/j.gastro.2011.10.001
Small-area Variations and Sociodemographic Correlates for the Incidence of Crohn's Disease and Ulcerative Colitis, American Journal of Epidemiology, vol.154, issue.4 ,
DOI : 10.1093/aje/154.4.328
The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America/ a systematic review, Aliment Pharmacol Ther, vol.16, pp.51-60, 2002. ,
Inflammatory bowel diseases : a disease(s) of modern times ? Is incidence still increasing ?, World J Gastroenterol, vol.14, issue.1036, pp.5491-5499, 2008. ,
Recent Trends in the Prevalence of Crohn???s Disease and Ulcerative Colitis in a Commercially Insured US Population, Digestive Diseases and Sciences, vol.132, issue.2, pp.519-525, 2013. ,
DOI : 10.1007/s10620-012-2371-5
The Epidemiology and Phenotype of Crohn???s Disease in the Chinese Population, Inflammatory Bowel Diseases, vol.10, issue.5, pp.646-51, 2004. ,
DOI : 10.1097/00054725-200409000-00022
Incidence and prevalence rates of inflammatory bowel diseases, in midwestern of S??o Paulo State, Brazil, midwester of Sao Paulo State, pp.20-25, 2009. ,
DOI : 10.1590/S0004-28032009000100009
Epidemiology and clinical course of Crohn's disease: Results from observational studies, World Journal of Gastroenterology, vol.18, issue.15, pp.1723-1731, 2012. ,
DOI : 10.3748/wjg.v18.i15.1723
INFLAMMATORY BOWEL DISEASE IN PEDIATRIC AND ADOLESCENT PATIENTS, Gastroenterology Clinics of North America, vol.28, issue.2, pp.445-58, 1999. ,
DOI : 10.1016/S0889-8553(05)70064-9
Patterns of Complementary and Alternative Medicine Use in a Population of Pediatric Patients with Inflammatory Bowel Disease, Inflammatory Bowel Diseases, vol.10, issue.5, pp.599-605, 2004. ,
DOI : 10.1097/00054725-200409000-00015
Approach to corticosteroid-dependent and corticosteroid-refractory Crohn's disease, Inflammatory Bowel Diseases, vol.7, issue.S1, pp.23-32, 2001. ,
DOI : 10.1002/ibd.3780070506
Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects, Journal of Crohn's and Colitis, vol.4, issue.4, pp.355-66, 2010. ,
DOI : 10.1016/j.crohns.2010.04.004
European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis, Gut, vol.55, issue.suppl_1, pp.5-15, 2006. ,
DOI : 10.1136/gut.2005.081950a
Disponible sur <http (22) Amgen Website Amgen and AstraZeneca Announce Collaboration to Jointly Develop and Commercialize Clinical-Stage Inflammation Portfolio. [en ligne] Disponible sur : http://wwwext.amgen.com/media/media_pr_detail.jsp?releaseID=1679295 (23) European Medicines Agency (EMA). Entyvio. Autorisation details, Disponible sur, p.278, 2014. ,
Review: Anti-adhesion molecule therapy for inflammatory bowel disease, Therapeutic Advances in Gastroenterology, vol.354, issue.2, pp.2-001751 ,
DOI : 10.1177/1756283X10373176
antibody that specifically alters trafficking of gut-homing T cells, British Journal of Pharmacology, vol.60, issue.S1, pp.51-68, 2013. ,
DOI : 10.1111/bph.12134
Notice to Applicants, medicinal products for human use, Disponible sur, pp.5-2008, 2008. ,
General Overview of eCTD [en ligne]. [ Consulté le 10, Disponible sur, 2011. ,
Quality of biotechnological products: Viral safety evaluation of biotechnological products derived from cell lines of human or animal origins, 2014. ,
Disponible sur Guideline on virus safety evaluation of investigational medicinal products, Disponible sur, 2005. ,
Concept paper on the revision of the guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins CHMP, Disponible sur C500003603.pdf (35) European Medicines Agency (EMA) 2014. [en ligne]. [Consulté le 17 Disponible sur, 1999. ,
pdf (36) ICH.Preclinical safety evaluation of biotechnology-derived pharmaceutical S6(R1), 1997. ,
Disponible sur : http://www.ich.org/fileadmin The TeGenero incident and the Duff Report conclusions: a series of unfortunate events or an avoidable event?, Toxicol Pathol, vol.17, issue.373, pp.372-83, 2009. ,
PARALLEL IMPORTS AND INNOVATION IN AN EMERGING ECONOMY: THE CASE OF INDIAN PHARMACEUTICALS, Health Economics, vol.42, issue.4, pp.1286-99, 2012. ,
DOI : 10.1002/hec.1790
Le marché pharmaceutique dans le monde et en France : Bilan et Perspective, 2009. ,
Role of FDA's drug information centers, American Journal of Health-System Pharmacy, vol.65, issue.9, pp.803-808, 2008. ,
DOI : 10.2146/ajhp070525
High incidence of inflammatory bowel disease in ,
a prospective population base australian incidence study, Inflamm Bowel Dis, vol.16, pp.1550-1556, 2010. ,
High incidence of Crohn??s disease in Canterbury, New Zealand: Results of an epidemiologic study, Inflammatory Bowel Diseases, vol.12, issue.10, pp.936-979, 2006. ,
DOI : 10.1097/01.mib.0000231572.88806.b9
Estimating the Potential Annual Welfare Impact of Innovative Drugs in Use in Switzerland, Frontiers in Public Health, vol.10, issue.48, p.48, 2014. ,
DOI : 10.3389/fpubh.2014.00048
Maladie de Crohn et colite ulcéreuse -l'essentiel pour les non-gastro-entérologues, Forum Med Suisse, vol.11, issue.47, pp.718-744, 2011. ,
Efficient clinical trials in Japan: Bridging studies versus participation in global clinical trials, The Journal of Clinical Pharmacology, vol.42, issue.2, pp.438-483, 2014. ,
DOI : 10.1002/jcph.216
The pharmerging future. The business magazine of Pharma, 2009. ,
Current development in regulation of similar biotherapeutic products in Brazil, Biologicals, vol.39, issue.5, pp.308-319, 2011. ,
DOI : 10.1016/j.biologicals.2011.06.021
Changes in the incidence of inflammatory bowel disease: what does it mean? European journal of internal medicine, pp.191-197, 2000. ,
Evaluation of the Pediatric Crohn Disease Activity Index: A Prospective Multicenter Experience, Journal of Pediatric Gastroenterology and Nutrition, vol.41, issue.4, pp.416-437, 2005. ,
DOI : 10.1097/01.mpg.0000183350.46795.42
Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort, Gastroenterology, vol.117, issue.1, pp.49-57, 1999. ,
DOI : 10.1016/S0016-5085(99)70549-4
A national survey on the patterns of treatment of inflammatory bowel disease in Canada, BMC Gastroenterology, vol.95, issue.1, p.10, 20035. ,
DOI : 10.1111/j.1572-0241.2000.02261.x
Relationship between disease severity, quality of life and health-care resource use in a cross-section of Australian patients with Crohn's disease, Journal of Gastroenterology and Hepatology, vol.32, issue.8, pp.1306-1318, 2007. ,
DOI : 10.1097/01.MIB.0000218762.61217.4a
Annual cost of care for Crohn's disease: a payor perspective, The American Journal of Gastroenterology, vol.117, issue.8, pp.1955-60, 2000. ,
DOI : 10.1111/j.1572-0241.2000.01779.x
Inflammatory Bowel Disease, Journal of Clinical Gastroenterology, vol.14, issue.4, pp.309-326, 1992. ,
DOI : 10.1097/00004836-199206000-00009
Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study, Gut, vol.53, issue.10, pp.1471-1479, 2004. ,
DOI : 10.1136/gut.2004.041616
Remission in Patients with Crohn's Disease is Associated with Improvement in Employment and Quality of Life and a Decrease in Hospitalizations and Surgeries, The American Journal of Gastroenterology, vol.7, issue.10, pp.91-97, 2004. ,
DOI : 10.1111/j.1572-0241.2001.03878.x
Effect of phenotype on health care costs in Crohn's disease: A European study using the Montreal classification, J Crohn's Colitis, vol.1, issue.2, pp.87-96, 2007. ,
Role of ASCA and the NOD2/CARD15 mutation Gly908Arg in predicting increased surgical costs in Crohn's disease patients: a project of the European Collaborative Study Group on Inflammatory Bowel Disease, Inflamm Bowel Dis, vol.13, issue.7, pp.874-81, 2007. ,
Direct Health Care Costs of Crohn's Disease and Ulcerative Colitis in US Children and Adults, Gastroenterology, vol.135, issue.6, pp.1907-1920, 2008. ,
DOI : 10.1053/j.gastro.2008.09.012
Hospitalisations and surgery in Crohn's disease, Gut, vol.61, issue.4 ,
DOI : 10.1136/gutjnl-2011-301397
Health Care Resource Utilization in Inflammatory Bowel Disease, Clinical Gastroenterology and Hepatology, vol.4, issue.6, pp.731-774, 2006. ,
DOI : 10.1016/j.cgh.2006.02.013
Direct Medical Cost of Managing IBD Patients: A Canadian Population-based Study, Inflammatory Bowel Diseases, vol.18, issue.8, pp.1498-508, 2011. ,
DOI : 10.1002/ibd.21878
Inflammatory Bowel Diseases: Health Care and Costs in Sweden in 1994, Scandinavian Journal of Gastroenterology, vol.13, issue.24, pp.1134-1143, 1997. ,
DOI : 10.1097/00004836-199206000-00010
Décès selon la cause, Chapitre XI : Maladies de l'appareil digestif (K00 à K93) le groupe d'âge et le sexe, Canada, annuel (nombre) Tableau, pp.102-0531 ,
related-connexes-fra.htm (73), www.statcan.gc.ca, 2008000. ,
Guide méthodologiques ;Choix méthodologiques pour l'évaluation économique à la HAS [en ligne]. [Consulté le 23/06 Disponible sur : http://www.hassante .fr/portail/upload/docs/application/pdf/2011-11/guide_methodo_vf.pdf (75) : Avis relatif aux prix de spécialités pharmaceutiques publiés en application de l'article L.162-16-6 du code de la sécurité sociale, 1998. ,
Briefing document for the joint meeting of the gastrointestinal drugs advisory committee and drug safety committee and risk management advisory committee. 2013. [en ligne]. [Consulté le 24 An evaluation of utility measurement in Crohn's disease, Disponible sur, pp.265-76, 1997. ,
Management for severe Crohn's disease: A lifetime cost-utility analysis, International Journal of Technology Assessment in Health Care, vol.88, issue.03, pp.274-283, 2004. ,
DOI : 10.1016/S0140-6736(78)92524-2
Comment anticiper l'évaluation de l'intérêt de santé publique des médicaments ? Thérapie, pp.417-442, 2007. ,
Unité méthodologie et études post-inscription : Les études post-inscription sur les technologies de santé (médicaments, dispositifs médicaux et actes) ,
Avis d'efficience : Etapes d'élaboration ,
Avis d'efficience : Format de l'avis d'efficience ,